Market closedNon-fractional
Cytosorbents/CTSO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cytosorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Ticker
CTSO
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Princeton, United States
Employees
186
Website
www.cytosorbents.com
Cytosorbents Metrics
BasicAdvanced
$56M
Market cap
-
P/E ratio
-$0.58
EPS
0.62
Beta
-
Dividend rate
Price and volume
Market cap
$56M
Beta
0.62
Financial strength
Current ratio
1.489
Quick ratio
1.145
Long term debt to equity
77.763
Total debt to equity
93.047
Interest coverage (TTM)
-269.37%
Management effectiveness
Return on assets (TTM)
-32.65%
Return on equity (TTM)
-115.03%
Valuation
Price to revenue (TTM)
1.328
Price to book
2.97
Price to tangible book (TTM)
2.97
Price to free cash flow (TTM)
-2.051
Growth
Revenue change (TTM)
3.50%
Earnings per share change (TTM)
-18.08%
3-year revenue growth (CAGR)
-5.08%
3-year earnings per share growth (CAGR)
40.76%
What the Analysts think about Cytosorbents
Analyst Ratings
Majority rating from 2 analysts.
Cytosorbents Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.7M
12.79%
Net income
-$6.3M
8.62%
Profit margin
-64.94%
-3.71%
Cytosorbents Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.21
-$0.13
-$0.12
-
Expected
-$0.11
-$0.14
-$0.14
-$0.12
-$0.09
Surprise
24.44%
52.17%
-5.45%
0.00%
-
Cytosorbents News
AllArticlesVideos
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
GlobeNewsWire·1 week ago
CytoSorbents Secures $20 Million Credit Facility
GlobeNewsWire·4 weeks ago
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytosorbents stock?
Cytosorbents (CTSO) has a market cap of $56M as of July 27, 2024.
What is the P/E ratio for Cytosorbents stock?
The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of July 27, 2024.
Does Cytosorbents stock pay dividends?
No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cytosorbents dividend payment date?
Cytosorbents (CTSO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytosorbents?
Cytosorbents (CTSO) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Cytosorbents stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.